bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Significant Drop in Short Interest

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the target of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 251,900 shares, a decline of 36.5% from the January 31st total of 396,800 shares. Approximately 2.7% of the company’s shares are short sold. Based on an average daily volume of 177,700 shares, the days-to-cover ratio is presently 1.4 days.

bioAffinity Technologies Trading Down 20.2 %

Shares of NASDAQ:BIAF traded down $0.08 on Tuesday, hitting $0.33. The company had a trading volume of 87,724 shares, compared to its average volume of 167,961. The firm’s 50-day simple moving average is $0.78 and its two-hundred day simple moving average is $1.24. The firm has a market capitalization of $5.10 million, a price-to-earnings ratio of -0.39 and a beta of 2.95. The company has a quick ratio of 1.01, a current ratio of 1.02 and a debt-to-equity ratio of 0.18. bioAffinity Technologies has a 1 year low of $0.30 and a 1 year high of $3.62.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC lifted its stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,304 shares of the company’s stock after purchasing an additional 26,304 shares during the quarter. Sheaff Brock Investment Advisors LLC owned about 0.30% of bioAffinity Technologies worth $42,000 as of its most recent filing with the Securities & Exchange Commission. 1.64% of the stock is currently owned by institutional investors and hedge funds.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.